Evotec AG (EVO) has released an update.
Evotec AG reports a slight 2% revenue growth to €390.8 million in the first half of 2024, driven by a 50% increase in Just-Evotec Biologics revenues, despite a 7% decrease in the Shared R&D segment. The company faces increased costs leading to an adjusted EBITDA of €(0.5) million, down from €33.9 million in the previous year, and has refined its full-year revenue guidance to €790 – 820 million. Additionally, Evotec announces several strategic partnerships and a new CEO, Dr. Christian Wojczewski, to navigate through a challenging market environment.
For further insights into EVO stock, check out TipRanks’ Stock Analysis page.
